



## Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals

Frederiksen, Simona Denise ; Karlskov-Mortensen, Peter; Pant, Sameer D.; Guerin, Maryse; Lesnik, Philippe; Jørgensen, Claus B.; Cirera Salicio, Susanna; Bruun, Camilla Vibeke Sichlau; Mark, Thomas; Fredholm, Merete

*Published in:*  
PLoS ONE

*DOI:*  
[10.1371/journal.pone.0178828](https://doi.org/10.1371/journal.pone.0178828)

*Publication date:*  
2017

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY](https://creativecommons.org/licenses/by/4.0/)

*Citation for published version (APA):*  
Frederiksen, S. D., Karlskov-Mortensen, P., Pant, S. D., Guerin, M., Lesnik, P., Jørgensen, C. B., ... Fredholm, M. (2017). Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals. *PLoS ONE*, 12(6), [e0178828]. <https://doi.org/10.1371/journal.pone.0178828>

RESEARCH ARTICLE

# Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals

Simona D. Frederiksen<sup>1</sup>, Peter Karlskov-Mortensen<sup>1</sup>, Sameer D. Pant<sup>2</sup>, Maryse Guerin<sup>3</sup>, Philippe Lesnik<sup>3</sup>, Claus B. Jørgensen<sup>1</sup>, Susanna Cirera<sup>1</sup>, Camilla S. Bruun<sup>1</sup>, Thomas Mark<sup>4</sup>, Merete Fredholm<sup>1\*</sup>

**1** Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, **2** School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, Australia, **3** INSERM UMR\_S1166, Integrative Biology of Atherosclerosis Team, Paris, France, **4** Novo Nordisk, Scandinavia AB, Region Denmark, Maaloev, Denmark

☉ These authors contributed equally to this work.

\* [mf@sund.ku.dk](mailto:mf@sund.ku.dk)



**OPEN ACCESS**

**Citation:** Frederiksen SD, Karlskov-Mortensen P, Pant SD, Guerin M, Lesnik P, Jørgensen CB, et al. (2017) Haplotypes on pig chromosome 3 distinguish metabolically healthy from unhealthy obese individuals. PLoS ONE 12(6): e0178828. <https://doi.org/10.1371/journal.pone.0178828>

**Editor:** Gudrun A. Brockmann, Humboldt-Universität zu Berlin, GERMANY

**Received:** January 3, 2017

**Accepted:** May 19, 2017

**Published:** June 1, 2017

**Copyright:** © 2017 Frederiksen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper except SNP genotype information, which is available from: doi:[10.5061/dryad.3jj7f](https://doi.org/10.5061/dryad.3jj7f).

**Funding:** The authors acknowledge the financial support by The Danish Independent Research Council Grant Number DFF 1335-00127. The coauthor Thomas Mark is presently employed by Novo Nordisk, however, at the time when the research generating the data presented in this manuscript was conducted, he was employed as Associate Professor at University of Copenhagen.

## Abstract

We have established a pig resource population specifically designed to elucidate the genetics involved in development of obesity and obesity related co-morbidities by crossing the obesity prone Göttingen Minipig breed with two lean production pig breeds. In this study we have performed genome wide association (GWA) to identify loci with effect on blood lipid levels. The most significantly associated single nucleotide polymorphisms (SNPs) were used for linkage disequilibrium (LD) and haplotype analyses. Three separate haploblocks which influence the ratio between high density lipoprotein cholesterol and total cholesterol (HDL-C/CT), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) levels respectively were identified on Sus Scrofa chromosome 3 (SSC3). Large additive genetic effects were found for the HDL-C/CT and LDL-C haplotypes. Haplotypes segregating from Göttingen Minipigs were shown to impose a positive effect on blood lipid levels. Thus, the genetic profile of the Göttingen Minipig breed seems to support a phenotype comparable to the metabolic healthy obese (MHO) phenotype in humans.

## Introduction

Obesity is defined as excessive accumulation of fat in the body to the extent that it may have a negative effect on health. According to the World Health Organization (WHO), in 2016 obesity had more than doubled worldwide since 1980. Obesity can be socially stigmatizing, however, in itself it is not the primary health problem. Rather, it is the co-morbidities such as cardiovascular disease (CVD) and type 2 diabetes (T2D) which pose the major health problems. Common to many of the co-morbidities is an unhealthy metabolic profile with insulin resistance and dyslipidemia characterized by elevated triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels and by decreased high-density lipoprotein cholesterol

Novo Nordisk has not contributed any funding to the research presented in this manuscript. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors declare no conflict of interest. The coauthor Thomas Mark is presently employed by Novo Nordisk, however, at the time when the research generating the data presented in this manuscript was conducted, he was employed as Associate Professor at University of Copenhagen. Neither at the time when the study was conducted nor now, have there been any competing interests with activities at Novo Nordisk. Thus, Thomas Mark's present affiliation to Novo Nordisk does not alter our adherence to PLOS ONE policies on sharing data and materials.

(HDL-C) concentrations [1]. Approximately 25% of obese humans do, however, not present the metabolic complications and do not suffer from an increased susceptibility towards obesity related diseases [2, 3]. These individuals are characterized as 'metabolically healthy obese' (MHO) [4].

To understand why MHO individuals have a better prognosis than the metabolically unhealthy individuals it is relevant to elucidate the genetic mechanisms underlying regulation of blood lipids such as cholesterol and TG.

Cholesterol is a ubiquitous steroid and a vital component of cellular membranes in vertebrates. But at the same time, subendothelial accumulation of cholesterol is the cause of atherosclerotic lesions leading to vascular diseases, heart attacks, aortic aneurysms and peripheral vascular diseases [5] which, altogether, represent the most frequent causes of demise in the industrialized world [6].

Cholesterol is transported in plasma in lipoprotein particles. These consist of a major structural apolipoprotein, peripheral apolipoproteins, structural lipids (phospholipids and cholesterol) and a cargo of TG and steryl esters. Dietary lipids are absorbed via the small intestine and packaged as TG into large particles known as chylomicrons (CM) which distribute lipids throughout the body for direct use and storage. CM remnants return to the liver where the remaining lipid cargo enters hepatic lipid pathways and a second class of lipoprotein particles is produced; the very low density lipoproteins (VLDL). Like CM, VLDL distributes TG to the periphery. As VLDL delivers TG they shrink and shed peripheral apolipoproteins, hence the proportion of cholesterol increases and VLDL becomes low-density lipoproteins (LDL). Both VLDL and LDL are characterized by the major structural apolipoprotein APOB. LDL can bind to cells expressing the LDL-receptor (LDLR) and as such, LDL acts as an efficient cholesterol delivery system into cells [5].

The reverse transport of cholesterol from the periphery to the liver is mediated by high-density lipoproteins (HDL) containing the major structural apolipoprotein APOA1. Nascent HDL particles contain few lipids but collect free cholesterol and phospholipids from peripheral tissues. Different mechanisms enrich the HDL particles with lipids, which ultimately are delivered to the liver via Scavenger Receptor B1 (SCARB1) for subsequent excretion with the bile [5].

Heritability for LDL-C and HDL-C levels in humans are estimated to be around 70%. [7] Large-scale genome wide association studies (GWAS) in humans have discovered over 150 common genetic variants associated with plasma lipids [8]. However, these loci only explain a small fraction of the total variance in blood lipids [9] and the bulk of genetic factors for dyslipidemia are still unaccounted for.

A way to elucidate novel mechanisms involved in blood lipid regulation is to study animal models. Animal models provide the benefits of a strictly controlled diet and environment which is impossible in large human studies. Consequently, random noise is greatly reduced and a corresponding increase in power is presumed when animal models are used to study human conditions. Also, the individual breeds are genetically more homogeneous than humans due to domestication and artificial selection [e.g. ref. 10]. GWAS [11] and quantitative trait locus (QTL) mapping [12] have been performed in mice to identify loci in the genome with effect on blood lipids. But more frequently, spontaneous dyslipidemic and genetically engineered mouse models have been used to study the effect of specific dyslipidemia associated genes first identified in human GWAS studies [13]. However, market differences in metabolism and adipose tissue biology exists between rodents and humans [e.g. ref. 14].

The pig is an animal model with a close similarity to humans in body size, physiology, organ development and disease progression. It has been widely used as a model for cardiovascular and metabolic diseases [15]. The presence of atherosclerotic lesions in aorta was

described in pigs as early as 1954 [16]. The close similarity to vascular lesions in human atherosclerosis have later been confirmed [17, 18], and the pig has proved its value as a model for this disease [19].

In the present study, a GWAS aimed at identifying loci with effect on blood lipid levels is reported. The GWAS was performed in two pig crosses established by using Göttingen Minipig as the parental boar line in both crosses whereas Duroc and Yorkshire production pigs were used as parental sow lines in the two crosses respectively. The Göttingen Minipig is an obesity prone pig breed [20] often used in studies of obesity, diabetes and metabolic syndrome [21–24], whereas Duroc and Yorkshire pigs have been bred for leanness for decades. Haplotypes were defined around the most significantly associated single nucleotide polymorphisms (SNPs), and the effect of the haplotypes with the highest additive effects were studied further.

## Materials and methods

### Experimental animal model, sample collection and blood lipid analysis

Two populations were produced as F2 crosses using purebred Göttingen Minipig (M), Duroc (D) and Yorkshire (Y) as parental lines (Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark; DanBred International, Herlev, Denmark). The Minipig-Duroc (MD) crossbred F1 animals were founded by seven M boars and seven D sows and 28 F1 MD gilts and 16 F1 MD boars were used to produce 285 F2 animals. Similarly, the Minipig-Yorkshire (MY) crossbred F1 animals were founded by seven M boars and seven Y sows and 279 F2 animals were produced by 26 MY gilts and 13 MY boars (for further information see [25, 26]).

All pigs were raised under controlled environmental conditions and fed the same diet ad libitum. The project was approved by the Danish Animal Experiments Inspectorate. Animal care and maintenance were conducted according to the Danish “Act about Animal Husbandry” and “Animal Protection Act” (Act 432, July 9, 2004; Act 1150, Sep. 12, 2015). All pigs were housed at a regular pig farm, and slaughtered at a commercial slaughterhouse by stunning and bleeding under veterinary supervision.

Blood samples for blood lipid analysis were drawn from the jugular vein at about two month of age ( $63 \pm 10$  days, abbreviated Age1) and at slaughter ( $242 \pm 48$  days, abbreviated Age2). Plasma lipid levels were assayed by standardized techniques using a Konelab 20 Clinical Chemistry Analyzer (Thermo Scientific, Sweden) and commercial reagent kits from Roche Diagnostics for Total Cholesterol (CT) and from ThermoElectron for TG and HDL-C levels (direct method). LDL-C levels were calculated using the Friedewald formula. Observations  $>5$  SD from the mean were considered outliers and excluded. Box-Cox transformation was used to adjust for non-normality. After transformation, skewness and kurtosis were calculated for each phenotypic distribution and Q-Q plots were made to evaluate normality.

### Estimation of genetic parameters

Genetic parameters were estimated using Best Linear Unbiased Prediction (BLUP) based on Average-Restricted Maximum Likelihood (AI-REML) using DMU version 6, release 5.2 [27]. Variance components were estimated using two different univariate models depending on whether the phenotypes were measured at Age1 (Model 1) or Age2 (Model 2):

$$1) \quad y_i = \mu + \text{SEX}_i + \text{CROSS}_i + \gamma(\text{AGE}_i) + \zeta A_i + \varepsilon_i$$

$$2) \quad y_i = \mu + \text{SEX}_i + \text{CROSS}_i + \gamma_1(\text{AGE}_i) + \gamma_2(\text{AGE}_i)^2 + \zeta A_i + \varepsilon_i$$

where  $y$  is the phenotype for animal  $i$ ,  $\mu$  is the population mean, SEX and CROSS are fixed

effects for sex and cross (MD or MY) for animal *i*, AGE for animal *i* is a covariate with regression coefficient  $\gamma$  and *A* is the additive genetic effect for animal *i* with the regression coefficient  $\xi$ .  $\epsilon_i$  is the residual error. *A* and  $\epsilon$  are assumed to be independent and normally distributed with variances  $A\sigma_{ANIMAL}^2$  and  $I\sigma_\epsilon^2$ , respectively. *A* is the additive genetic relationship matrix based on pedigree information,  $\sigma_{ANIMAL}^2$  the additive genetic variance, *I* an identity matrix of appropriate size and  $\sigma_\epsilon^2$  the residual error variance.

A bivariate linear mixed model was fitted to estimate phenotypic and genetic correlations between pairs of traits (Trait 1 and Trait 2):

$$\begin{bmatrix} y_1 \\ y_2 \end{bmatrix} = \begin{bmatrix} X_1 & 0 \\ 0 & X_2 \end{bmatrix} \begin{bmatrix} b_1 \\ b_2 \end{bmatrix} + \begin{bmatrix} Z_1 & 0 \\ 0 & Z_2 \end{bmatrix} \begin{bmatrix} a_1 \\ a_2 \end{bmatrix} + \begin{bmatrix} e_1 \\ e_2 \end{bmatrix}$$

where  $y_1$  and  $y_2$  are vectors of the transformed phenotypic measurements of Trait 1 and Trait 2 respectively.  $X_1$  and  $X_2$  are design matrices connecting the measurements to  $b_1$  and  $b_2$  which are vectors of the environmental fixed effects, while  $Z_1$  and  $Z_2$  are design matrices linking the measurements to  $a_1$  and  $a_2$  which are vectors for the random genetic effects for each trait. Finally,  $e_1$  and  $e_2$  are vectors of the random environmental effects. The effects fitted in the bivariate linear mixed models are the same as the ones fitted in the univariate linear mixed models. When fitting the bivariate model, the non-diagonals of the additive genetic variance and covariance matrix *G* for animal effects and the variance and covariance matrix *R* for random residual effects were included as follows:

$$A\sigma_A^2 = G = \begin{bmatrix} A\sigma_{A1}^2 & A\text{cov}_{A12} \\ A\text{cov}_{A21} & A\sigma_{A2}^2 \end{bmatrix} \quad I\sigma_e^2 = R = \begin{bmatrix} I\sigma_{E1}^2 & I\text{cov}_{E12} \\ I\text{cov}_{E21} & I\sigma_{E2}^2 \end{bmatrix}$$

where  $\text{cov}_{A12} = \text{cov}_{A21}$  is the additive genetic covariance and  $\text{cov}_{E12} = \text{cov}_{E21}$  the random residual covariance between Trait 1 and 2. The phenotypic covariance  $\text{cov}_{P12} = \text{cov}_{P21}$  between Trait 1 and 2 can be calculated as:  $\text{cov}_{P12} = \text{cov}_{A12} + \text{cov}_{E12}$  [28].

## Genotyping and Quality Control

Each animal was genotyped using the 60k porcine Illumina SNPchip. Sex chromosomes were excluded from the single-marker analyses. The Sus Scrofa 10.2 pig genome assembly was used to derive map positions for all SNPs. After genotyping, quality control (QC) was conducted using GenABEL version 1.8–0 [29] excluding: animals and SNPs with more than 5% missing genotypes; SNPs with a minor allele frequency (MAF) less than 5%; SNPs that significantly deviated from Hardy-Weinberg equilibrium (HWE) at a significance threshold of  $p < 1E-05$ . After QC, 549 pigs and 44,554 SNPs remained.

## GWAS using single-marker test and estimation of SNP effects

GWAS was carried out for each phenotype using a single-marker test as implemented in GenABEL [30]. The analyses were performed in two steps: In step 1, the polygenic linear mixed models were defined as Model 1 (for Age1) and Model 2 (for Age2) where  $A_i$  is the random additive polygenic effect for animal *i* based on identity by state (IBS).  $A_i$  is assumed to be normally distributed with a (co)variance of  $G\sigma_{ANIMAL}^2$  where *G* is the genomic relationship matrix and  $\sigma_{ANIMAL}^2$  the additive polygenic variance. Estimation of effects was performed by means of maximum likelihood (ML) [31].

Step 2 use estimated residuals from step 1 (contains part of the QTL variance) to estimate SNP effects [30]:

$$\hat{\epsilon}_i = \mu + SNP_m + \epsilon_m$$

where  $\hat{\epsilon}_i$  is the estimated residual error from step 1,  $\mu$  is the mean,  $SNP_m$  is assumed a fixed effect with 3 genotype scores 0, 1 and 2 referring to the number of minor allele copies for the  $m$ 'th SNP and  $\epsilon_m$  is the residual error. Each single SNP was modeled independently. The allele substitution effect of the  $m$ 'th SNP was calculated as the average phenotypic change when replacing a major allele with the minor allele [32].

SimpleM [33–35] was used to correct for multiple testing by calculating the effective number of independent tests  $M_{\text{eff}} = 12916$ . Missing genotypic values were replaced with the common allele genotype in the genotype matrix prior to the analysis. It resulted in a cut off value of  $-\log_{10}(0.05/12916) = 5.41$  corresponding to a nominal significance level ( $\alpha$ ) of  $3.87 \times 10^{-6}$ .

For each significant SNP, the phenotypic variance explained by the SNP was calculated as [36]:

$$V_{\text{SNP}} = V_m = 2q_m(1 - q_m)\hat{SNP}_m^2$$

where  $V_m$  is the phenotypic variance explained by the  $m$ 'th SNP,  $q_m$  is MAF for the  $m$ 'th SNP and  $\hat{SNP}_m$  is the estimated effect for the  $m$ 'th SNP. The variance explained by the SNP is assumed to be due to additive genetic variance. The proportion of additive genetic variance explained by each SNP was calculated as  $V_{\text{SNP}} / \sigma_A^2$ . The additive genetic effect ( $\alpha$ ) for each top-SNP was calculated using BLUP as implemented in DMU where the effect of having 0, 1 or 2 copies of a specific SNP was fitted in the models described above (Model 1 and Model 2).

### Linkage disequilibrium and haplotype analysis

The method described by Gabriel et al.(2002) [37] as implemented in Haploview [38] was used to define haploblocks around the top SNPs identified in the GWAS. Default parameters were used except for “Fraction of strong LD in informative comparisons” which was set to  $>0.80$  (default  $>0.95$ ). Phased haplotypes for each haploblock for each individual were estimated using the—hap-phase option in Plink [39]. The additive genetic effect of each haplotype was estimated using BLUP by fitting the haplotype as a covariate in the models described above (Model 1 and Model 2). Effect were fitted for one haplotype variant at a time by computing the effect of having 0, 1 or 2 copies of that variant. Effects were only calculated for haplotype variants observed in the founder animals and not for variants found in less than 20 animals in the F2 population.

To evaluate haplotype effects in individuals with high- and low-BMI respectively, all F2 animals were sorted according to BMI and the one-third with highest BMI (high BMI) and lowest (low BMI) respectively were selected. Each of the groups were subdivided according to haplotypes in the HDL-C/CT and the LDL-C QTL regions and mean and standard deviation for BMI\_Age2, CT\_Age2, TG\_Age2, HDL-C/CT\_Age1, HDL-C\_Age2, HDL-C/CT\_Age2, LDL-C\_Age2 and LDL-C/HDL-C at Age2 were calculated separately using Students-t test for animals which were homozygous for either the GM or the Yorkshire/Duroc haplotypes in the HDL-C/CT and LDL-C QTL regions.

### Results

A moderate genetic correlation was found between Age1 and Age2 both in regard to LDL-C and HDL-C/CT, whereas, for TG there was no correlation between measurements at the two ages (see Table 1).

**Table 1. Genetic (r<sub>A</sub>) and phenotypic (r<sub>P</sub>) correlation between phenotypes measured at different age.**

Phenotypes		Correlation coefficients	
Trait 1	Trait 2	r <sub>A</sub> (SE)	r <sub>P</sub>
TG_Age1	TG_Age2	0.01 (0.28)	-0.07
LDL-C_Age1	LDL-C_Age2	0.41 (0.19)	0.31
HDL-C/CT_Age1	HDL-C/CT_Age2	0.21 (0.24)	0.29

Age1: 63 ± 10 days, Age1; Age2: 242 ± 48 days

<https://doi.org/10.1371/journal.pone.0178828.t001>

The GWA study resulted in the identification of several QTL regions below the nominal significance level on *sus scrofa* chromosome 3 (SSC3) (see Table 2). A single SNP on SSC3 at 124.7 Mb is associated with TG\_Age2, whereas, there is no indication for an association with TG\_Age1 at this position (data not shown). Conversely, the same loci on SSC3 are associated with LDL-C at Age 1 and Age 2 and the same is true for HDL-C/CT. The most significant associations for LDL-C are found around 125.6 Mb and the most significant SNPs for HDL-C/CT are found at 122.8 Mb.

LD analysis (Fig 1) revealed that the two top SNPs for HDL-C/CT\_Age1 and HDL-C/CT\_Age2 are located close together and belong to the same LD-block defined by six SNPs from 122.7–122.9 Mb (designated '1' in Fig 1). The top SNP's for TG\_Age2 and LDL-C\_Age1 and Age2 show minimal LD to surrounding SNPs and are not included in any LD blocks when default parameters in Haploview are used (results not shown). Relaxing the parameters for block definition, as described above, includes the top SNP for LDL-C\_Age2 into an LD block defined by 10 SNPs spanning a region from 125.6–125.9 Mb (designated '3' Fig 1), but the top SNP for LDL-C\_Age1 is still outside the LD block. In the same way the relaxed parameters include the top SNP for TG\_Age2 into a four SNP haploblock from 124.67–124.75 Mb (designated '2' in Fig 1) clearly separated from the HDL-C/CT and the LDL-C loci. The SNPs located in the haploblocks associated with the lipid levels are listed in SI 1.


The additive genetic effect of haplotypes present in more than 20 animals is shown in Table 3. The largest additive effects appear for the HDL-C/CT and LDL-C haplotypes for which there is also a clear breed specific segregation. For the HDL-C/CT associated haplotypes one specific haplotype, AAAGGG, impose a higher HDL-C/CT level. Twelve out of fourteen Göttingen Minipig founders are homozygous for this haplotype and the remaining two has one copy of AAAGGG. The haplotype GGGAAA, for which all Yorkshire founders are homozygous, has an equivalent negative effect, that is, animals with this haplotype have lower HDL-C/CT levels. The same trend is true for the haplotypes segregating from the Duroc

**Table 2. QTL regions and SNP effects.**

Phenotypes	Most significant SNP on SSC3									SNP effect
	SNP name	Position	P-value	MA	MAF	MAF (GM)	MAF (DD)	MAF (YY)	V <sub>SNP</sub> /σ <sub>A</sub> <sup>2</sup>	α (SE)
TG_Age2	ALGA0021201	124739382	3.35E-06	A	0.36	0.00	0.70	0.83	0.34	-0.02 (0.00)
LDL-C_Age1	ASGA0094490	125568713	1.34E-08	A	0.38	0.00	0.60	0.83	0.17	0.05 (0.01)
LDL-C_Age2	ASGA0106214	125592465	2.07E-07	A	0.20	0.41	0.00	0.00	0.13	-0.05 (0.01)
HDL-C/CT_Age1	ALGA0021148	122811986	2.12E-09	G	0.39	0.00	0.60	1.00	0.20	-0.04 (0.00)
HDL-C/CT_Age2	MARC0019977	122854537	3.91E-07	A	0.42	0.00	0.70	1.00	0.26	-0.03 (0.01)

MA: Minor allele; MAF: Minor allele frequency; MAF (GM), (DD), (YY): Minor allele frequency in the parental generation of Göttingen minipigs, Duroc and Yorkshire respectively; V<sub>SNP</sub>/σ<sub>A</sub><sup>2</sup>: Proportion of additive genetic variance explained by each SNP; α (SE): additive genetic effect for each top-SNP (standard error)

<https://doi.org/10.1371/journal.pone.0178828.t002>



**Fig 1. LD in a 2.8 Mb region (122.4–126.1 Mb) on *Sus Scrofa* chromosome 3.** Frames mark top SNPs for HDL-C/CT\_Age1, HDL-C/CT\_Age2, TG\_Age2, LDL-C\_Age1 and LDL-C\_Age2, in this order from left to right. Triangles indicate haploblock structure in the QTL region. Block 1: QTL for HDL-C/CT; Block 2: QTL for TG; Block 3: QTL for LDL-C.

<https://doi.org/10.1371/journal.pone.0178828.g001>

breed, and among the Duroc haplotypes, AGAAGA, has an even stronger negative effect compared to the Yorkshire haplotype on the HDL-C/CT level. The effect of the individual haplotypes is similar at Age 1 and Age 2 (data not shown).

For the LDL-C associated LD block, the haplotype AGGAGCCAAA originating from the Göttingen Minipig founders, decrease the LDL-C level. The Yorkshire founder specific

**Table 3. Haplotype effects—SSC3.**

Phenotype	Haplotype	Haploblock	Additive effect	SE	Origine*
HDL-C/CT	AAAGAA	1	-0.02	0.01	D
	AAAGGA		0.01	0.01	GM
	AAAGGG		0.04	0.00	GM
	AGAAGA		-0.07	0.01	D
	AGGAAA		-0.02	0.02	D
	GAAAGA		-0.02	0.02	D
	GGGAAA		-0.04	0.01	Y
TG Age2	AAAA	2	-0.02	0.00	Y, D
	GACA		0.01	0.00	GM, Y
	GGAA		-0.02	0.01	D
	GGCG		0.01	0.01	D
LDL-C	AGGAGCCAAA	3	-0.04	0.01	GM
	GAAAGAAACG		0.01	0.01	D
	GGAAGAAACG		-0.02	0.02	Y
	GGAAGAAGAG		0.03	0.02	Y
	GGAAGAAGCG		0.02	0.01	Y
	GGGAGCCAAA		0.01	0.01	GM
	GGGAGCCGAG		0.00	0.02	D
GGGGAACAAG	0.02	0.01	D		

Effect of haplotypes present in more than 20 animals in the population in the three QTL haploblocks

\*: GM = Göttingen Minipig; Y = Yorkshire; D = Duroc

<https://doi.org/10.1371/journal.pone.0178828.t003>



**Table 4. Effects of HDL-C/CT and LDL-C haplotypes with high additive effect in high- and low-BMI individuals.**

	BMI_Age2	CT_Age2	TG_Age2	HDL-C/CT Age1	HDL-C_Age2	HDL-C/CT Age2	LDL-C_Age2	LDL-C/HDL-C Age2	n
<b>High BMI</b>									
GM/GM	157.56 (14.00)	2.28 (0.49)	0.45 (0.18)	0.54 (0.07)	1.40 (0.31)	0.62 (0.07)	0.68 (0.27)	0.49 (0.17)	28
D/D or Y/Y	149.75 (16.05)	2.55 (0.55)	0.71 (0.35)	0.47 (0.06)	1.30 (0.35)	0.51 (0.10)	0.93 (0.33)	0.79 (0.46)	22
t-test	0.037468	0.034815	0.000744	0.00044	0.164139	7.38E-05	0.002637	0.001605	
<b>Low BMI</b>									
GM/GM	112.62 (9.38)	2.26 (0.84)	0.44 (0.23)	0.51 (0.10)	1.25 (0.54)	0.56 (0.10)	0.80 (0.35)	0.68 (0.31)	32
D/D or Y/Y	112.81 (6.00)	2.28 (0.67)	0.46 (0.17)	0.45 (0.07)	1.28 (0.44)	0.57 (0.11)	0.79 (0.39)	0.67 (0.41)	22
t-test	0.465747	0.464812	0.420131	0.017532	0.420304	0.379878	0.44152	0.462115	

Mean and standard deviation (in parentheses) for eight phenotypes in high and low BMI animals homozygous for the Göttingen Minipig haplotypes (GM/GM) or Yorkshire (Y/Y) or Duroc (D/D) haplotypes in haploblock 1 (HDL-C/CT) and 3 (LDL-C).

<https://doi.org/10.1371/journal.pone.0178828.t004>

haplotypes, GGAAGAAGAG and GGAAGAAGCG, increase LDL-C level; however, there is also one Yorkshire haplotype, GGAAGAAACG, which decreases LDL-C level. Two of the Duroc haplotypes increase the LDL-C level slightly. The effect of each haplotype is the same at Age 1 and Age 2 (data not shown) even though the blocks are only loosely in LD according to the LD analysis.

To further evaluate the phenotypic consequences of the haplotypes segregating from Göttingen Minipig and Yorkshire/Duroc respectively we compared lipid and TG levels in animals homozygous for either Göttingen Minipig haplotypes or the Duroc/Yorkshire haplotypes. The comparison was performed in the one-third of the F2 animals with the highest and one-third with lowest BMI, respectively. The mean BMI in the combined F2 population (564 animals) is 127±20 while in the selected high BMI group (136 animals) the mean BMI is 154±13, and in the selected low BMI group (132 animals) the mean BMI is 111±9. As seen in Table 4, within the low BMI group of animals there are no differences in TG and lipid values between the genetically diverse animals. However, when comparing animals homozygous for Göttingen Minipig haplotypes with animals homozygous for Yorkshire/Duroc haplotypes within the high BMI group of animals both TG and lipid values (except HDL-C) are significantly higher in animals with the Yorkshire/Duroc haplotypes.

## Discussion

In agreement with previously performed GWA studies in pigs [26, 40, 41], we have identified a QTL region influencing lipoprotein traits on SSC3. The homologous region on human chromosome 2 has also been implicated in the regulation of blood lipids in human GWA studies [42]. Our study shows that three separate haploblocks influence HDL-C/CT -, TG -, and LDL-C levels respectively (see Fig 1). The HDL-C/CT and HDL-C QTL loci flank the TG\_Age2 locus and thus, this 2.8 Mb region on SSC3 seems to encompass several loci with a regulatory effect on different plasma lipids. This is underpinned by the observation that the SSC3 locus affects HDL-C and LDL-C levels independent of age but for TG-levels there is only an association to TG\_Age2 and no evidence suggesting an association to TG\_Age1. This indicates that different genes or regulatory mechanisms in the region are responsible for effects on cholesterol and triglyceride levels, respectively. This is also in agreement with the observed correlations between phenotypes at different ages (Table 1) and the lack of a correlation between TG at Age1 and Age2.

There are no annotated known genes in the HDL-C/CT and TG associated SSC3 haploblocks in the Sscrofa 10.2 assembly but the gene encoding ras homolog family member B (*RHOB*) is located in the LDL-C associated haploblock. *RHOB* is a member of the RHO GTP-binding protein family which regulates expression of *CD36* [43]. *CD36* is a scavenger protein with high affinity for plasma lipoproteins including LDL and a high expression in tissues such as skeletal muscle, heart, mammary, epithelium and adipose tissue, with a very active fatty acid metabolism [44]. The gene encoding apolipoprotein B (*APOB*) is located at 125.23–125.35 Mb. It is an obvious candidate gene for lipid related traits but in the present study it is not included in associated LD-blocks even though it was covered by four SNPs with a MAF above the exclusion threshold. The gene encoding lipid droplet associated hydrolase (*LDAH*) is located at 125.42–125.53 Mb which is also outside the identified LD-blocks. Further studies including sequencing and genotyping of additional markers are warranted to ascertain LD structure and to identify genetic variation. It is very likely that the observed differences in blood lipids are caused by variation in regulatory components within the identified QTL regions in particular since a high number of different genes involved in regulation of lipoproteins are located within this region of the genome.

Investigation of the additive genetic effect of the most common haplotypes segregating within the F2 population indicates that the haplotypes originating from the Göttingen Minipig breed provide a healthier lipid profile compared to the haplotypes segregating from the Yorkshire and Duroc breeds. I.e., Göttingen Minipig haplotypes in haploblock 1 appears to increase HDL-C/CT compared to the Yorkshire and Duroc haplotypes, which have the opposite effect. Conversely, in haploblock 3 the Göttingen Minipig haplotype lowers the level of LDL-C and the Yorkshire and Duroc haplotype increases LDL-C level with the exception of the GGAA-GAAACG haplotype segregating from the Yorkshire breed. This effect is confirmed by comparing animals homozygous for the Göttingen Minipig and Duroc/Yorkshire haplotypes respectively within groups of animals with high and low BMI respectively. Within the high BMI group animals with Göttingen Minipig haplotypes have a significantly lower TG level, lower levels of LDL-C, and LDL-C/HDL-C ratio and higher ratio of HDL-C to CT (Table 4). Within the low BMI group there is no difference in the phenotypes between the two genetic variants. Thus, overall Göttingen Minipig seems to have a genotype that supports a more healthy blood lipid profile in spite of the fact that they are prone to obesity. Or conversely, pigs without the Göttingen Minipig haplotypes develop a more unhealthy, dyslipidemic profile together with obesity, compared to pigs with Göttingen Minipig haplotypes which uphold a healthy lipid profile despite development of severe obesity.

The Göttingen Minipig breed was developed in the 1960's using Minnesota Minipigs, Vietnamese Potbelly Pigs, and German Landrace as founders (Simianer and Köhn, 2010). A likely explanation for the MHO profile in Göttingen Minipigs is that the obesity prone minipig founders have been adapted to overcome obesity by natural selection. Thus, unexpectedly, the results presented here indicate that the Göttingen Minipig breed is not well suited for studies of the obesity related co-morbidities but may be a valuable model to advance understanding of the MHO phenotype in humans.

The MHO profile identified in our F2 population is comparable to the MHO profile in humans which appear to be protected against obesity related metabolic complications. However, although MHO is an important, emerging phenotype in humans no universally accepted definition has been established for this phenotype yet [45]. It is also debated to what extent MHO individuals will remain healthy [46, 47]. On the other hand, studying MHO subjects may lead to better intervention strategies for metabolically unhealthy obese people, and elucidate if they by lifestyle changes or by the use of medicine can switch to a better metabolic profile.

In conclusion, we have substantiated that different genetic loci have an effect on TG early and late in life. We have also substantiated that the genomic region close to genes implicated in lipoprotein metabolism (*RHOB*, *APOB*, *LDAH*) comprise regulatory elements of importance to the regulation of lipid metabolism. Interestingly, the largest additive genetic effects of the haplotypes identified in this study show that haplotypes segregating from the obesity prone Göttingen Minipig breed is able to uphold a healthy lipid profile despite development of obesity. Thus, the genetic profile of the Göttingen Minipig breed seems to support a phenotype comparable to the MHO phenotype in humans promoting this pig breed as a model for further studies of this particular phenotype. Our future studies will be directed at identification the genetic variation in the regulatory components involved in lipid metabolism and further genetic characterization of the healthy metabolic phenotype.

## Acknowledgments

We thank Tina Neergaard Mahler, Minna Baron Jakobsen, and Charlotte Bjørner Larsen for excellent technical assistance. We acknowledge the financial support by The Danish Independent Research Council Grant Number DFF 1335–00127.

## Author Contributions

**Conceptualization:** MF PKM CBJ SC CSB.

**Data curation:** SDF PKM SDP.

**Formal analysis:** SDF PKM SDP.

**Funding acquisition:** MF.

**Investigation:** SDF PKM SDP TM MF.

**Methodology:** SDF PKM SDP MG PL.

**Project administration:** MF.

**Resources:** MF.

**Supervision:** MF SDP TM.

**Validation:** MF TM.

**Visualization:** PKM.

**Writing – original draft:** SDF PKM MF.

**Writing – review & editing:** SDF PKM SDP MG PL CBJ SC CSB TM MF.

## References

1. Grundy SM. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. *Nature reviews Cardiology*. 2016; 13(2):74–5. Epub 2016/01/15. <https://doi.org/10.1038/nrcardio.2015.208> PMID: 26763537
2. Navarro E, Funtikova AN, Fito M, Schroder H. Can metabolically healthy obesity be explained by diet, genetics, and inflammation? *Molecular nutrition & food research*. 2015; 59(1):75–93. Epub 2014/11/25.
3. Bosello O, Donataccio MP, Cuzzolaro M. Obesity or obesities? Controversies on the association between body mass index and premature mortality. *Eating and weight disorders: EWD*. 2016. Epub 2016/04/05.
4. Blüher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. *Current Opinion in Lipidology*. 2010; 21(1):38–43. <https://doi.org/10.1097/MOL.0b013e3283346ccc> PMID: 19915462

5. Vance JE, Vance DE. *Biochemistry of Lipids, Lipoproteins and Membranes*. 5 ed. Amsterdam: Elsevier Science; 2008.
6. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Baha MJ, et al. Heart Disease and Stroke Statistics—2014 Update: A report from the American Heart Association. *Circulation*. 2014; 129(3):e28–e292. <https://doi.org/10.1161/01.cir.0000441139.02102.80> PMID: 24352519
7. Weiss LA, Pan L, Abney M, Ober C. The sex-specific genetic architecture of quantitative traits in humans. *Nat Genet*. 2006; 38(2):218–22. <https://doi.org/10.1038/ng1726> PMID: 16429159
8. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013; 45(11):1274–83. <https://doi.org/10.1038/ng.2797> PMID: 24097068
9. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010; 466(7307):707–13. <https://doi.org/10.1038/nature09270> PMID: 20686565
10. Groenen MA. A decade of pig genome sequencing: a window on pig domestication and evolution. *Genetics, selection, evolution: GSE*. 2016; 48:23. Epub 2016/03/31. <https://doi.org/10.1186/s12711-016-0204-2> PMID: 27025270
11. Pletcher MT, McClurg P, Batalov S, Su AI, Barnes SW, Lagler E, et al. Use of a dense single nucleotide polymorphism map for in silico mapping in the mouse. *PLoS biology*. 2004; 2(12):e393. Epub 2004/11/10. <https://doi.org/10.1371/journal.pbio.0020393> PMID: 15534693
12. Wang X, Paigen B. Genetics of Variation in HDL Cholesterol in Humans and Mice. *Circulation Research*. 2005; 96(1):27–42. <https://doi.org/10.1161/01.RES.0000151332.39871.13> PMID: 15637305
13. Kuivenhoven JA, Hegele RA. Mining the genome for lipid genes. *Biochimica et Biophysica Acta (BBA) —Molecular Basis of Disease*. 2014; 1842(10):1993–2009.
14. Arner P. Resistin: yet another adipokine tells us that men are not mice. *Diabetologia*. 2005; 48(11):2203–5. <https://doi.org/10.1007/s00125-005-1956-3> PMID: 16193286
15. Lunney JK. Advances in Swine Biomedical Model Genomics. *International journal of biological sciences*. 2007; 3(3):179–84. PMID: 17384736
16. Gottlieb H, Lalich JJ. The Occurrence of Arteriosclerosis in the Aorta of Swine. *The American Journal of Pathology*. 1954; 30(4):851–5. PMID: 13180692
17. Rapacz J, Hasler-Rapacz J, Taylor K, Checovich W, Attie A. Lipoprotein mutations in pigs are associated with elevated plasma cholesterol and atherosclerosis. *Science*. 1986; 234(4783):1573–7. PMID: 3787263
18. Prescott MF, McBride CH, Hasler-Rapacz J, Von Linden J, Rapacz J. Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B. *The American Journal of Pathology*. 1991; 139(1):139–47. PMID: 1853929
19. Hamamdzcic D, Wilensky RL. Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. *Journal of diabetes research*. 2013; 2013:761415. Epub 2013/07/12. <https://doi.org/10.1155/2013/761415> PMID: 23844374
20. Bollen PJ, Madsen LW, Meyer O, Ritskes-Hoitinga J. Growth differences of male and female Gottingen minipigs during ad libitum feeding: a pilot study. *Lab Anim*. 2005; 39(1):80–93. Epub 2005/02/11. <https://doi.org/10.1258/0023677052886565> PMID: 15703128
21. Johansen T, Hansen HS, Richelsen B, Malmlof R. The obese Gottingen minipig as a model of the metabolic syndrome: dietary effects on obesity, insulin sensitivity, and growth hormone profile. *Comparative medicine*. 2001; 51(2):150–5. Epub 2002/04/02. PMID: 11922179
22. Christoffersen B, Golozoubova V, Pacini G, Svendsen O, Raun K. The young Gottingen minipig as a model of childhood and adolescent obesity: influence of diet and gender. *Obesity*. 2013; 21(1):149–58. Epub 2013/03/19. <https://doi.org/10.1002/oby.20249> PMID: 23505180
23. Cirera S, Jensen MS, Elbrond VS, Moesgaard SG, Christoffersen BO, Kadarmideen HN, et al. Expression studies of six human obesity-related genes in seven tissues from divergent pig breeds. *Anim Genet*. 2014; 45(1):59–66. <https://doi.org/10.1111/age.12082> PMID: 24033492
24. Christoffersen B, Ribel U, Raun K, Golozoubova V, Pacini G. Evaluation of different methods for assessment of insulin sensitivity in Gottingen minipigs: introduction of a new, simpler method. *American journal of physiology Regulatory, integrative and comparative physiology*. 2009; 297(4):R1195–201. Epub 2009/08/28.
25. Kogelman LJ, Kadarmideen HN, Mark T, Karlskov-Mortensen P, Bruun CS, Cirera S, et al. An f2 pig resource population as a model for genetic studies of obesity and obesity-related diseases in humans: design and genetic parameters. *Front Genet*. 2013; 4:29. Epub 2013/03/22. <https://doi.org/10.3389/fgene.2013.00029> PMID: 23515185
26. Pant SD, Karlskov-Mortensen P, Jacobsen MJ, Cirera S, Kogelman LJ, Bruun CS, et al. Comparative Analyses of QTLs Influencing Obesity and Metabolic Phenotypes in Pigs and Humans. *PLoS One*.

- 2015; 10(9):e0137356. PubMed Central PMCID: PMC4562524. <https://doi.org/10.1371/journal.pone.0137356> PMID: 26348622
27. Madsen P, Jensen J, Labouriau R, Christensen O, Sahana G. DMU—A Package for Analyzing Multivariate Mixed Models in quantitative Genetics and Genomics. URL: [pureaudk/portal/files/82154310/Paperpdf](http://pureaudk/portal/files/82154310/Paperpdf). 2014.
  28. Wilson AJ, Reale D, Clements MN, Morrissey MM, Postma E, Walling CA, et al. An ecologist's guide to the animal model. *The Journal of animal ecology*. 2010; 79(1):13–26. Epub 2010/04/23. <https://doi.org/10.1111/j.1365-2656.2009.01639.x> PMID: 20409158
  29. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. *Bioinformatics (Oxford, England)*. 2007; 23(10):1294–6. Epub 2007/03/27.
  30. Amin N, van Duijn CM, Aulchenko YS. A genomic background based method for association analysis in related individuals. *PLoS One*. 2007; 2(12):e1274. Epub 2007/12/07. <https://doi.org/10.1371/journal.pone.0001274> PMID: 18060068
  31. Aulchenko YS, de Koning DJ, Haley C. Genomewide rapid association using mixed model and regression: a fast and simple method for genomewide pedigree-based quantitative trait loci association analysis. *Genetics*. 2007; 177(1):577–85. Epub 2007/07/31. <https://doi.org/10.1534/genetics.107.075614> PMID: 17660554
  32. Chen W-M, Abecasis GR. Family-Based Association Tests for Genomewide Association Scans. *The American Journal of Human Genetics*. 2007; 81(5):913–26. <https://doi.org/10.1086/521580> PMID: 17924335
  33. Gao X. Multiple testing corrections for imputed SNPs. *Genetic Epidemiology*. 2011; 35(3):154–8. <https://doi.org/10.1002/gepi.20563> PMID: 21254223
  34. Gao X, Becker LC, Becker DM, Starmer JD, Province MA. Avoiding the high Bonferroni penalty in genome-wide association studies. *Genetic Epidemiology*. 2010; 34(1):100–5. <https://doi.org/10.1002/gepi.20430> PMID: 19434714
  35. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genet Epidemiol*. 2008; 32(4):361–9. Epub 2008/02/14. <https://doi.org/10.1002/gepi.20310> PMID: 18271029
  36. Falconer D, Mackay T. *Introduction to Quantitative Genetics*. 4 ed. England: Longman Group Limited; 1996.
  37. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The Structure of Haplotype Blocks in the Human Genome. *Science*. 2002; 296(5576):2225–9. <https://doi.org/10.1126/science.1069424> PMID: 12029063
  38. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics (Oxford, England)*. 2005; 21(2):263–5. Epub 2004/08/07.
  39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics*. 2007; 81(3):559–75. Epub 2007/08/19. <https://doi.org/10.1086/519795> PMID: 17701901
  40. Manunza A, Casellas J, Quintanilla R, Gonzalez-Prendes R, Pena RN, Tibau J, et al. A genome-wide association analysis for porcine serum lipid traits reveals the existence of age-specific genetic determinants. *BMC genomics*. 2014; 15:758. Epub 2014/09/06. <https://doi.org/10.1186/1471-2164-15-758> PMID: 25189197
  41. Yang H, Huang X, Zeng Z, Zhang W, Liu C, Fang S, et al. Genome-Wide Association Analysis for Blood Lipid Traits Measured in Three Pig Populations Reveals a Substantial Level of Genetic Heterogeneity. *PLoS One*. 2015; 10(6):e0131667. Epub 2015/06/30. <https://doi.org/10.1371/journal.pone.0131667> PMID: 26121138
  42. Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. *Nat Genet*. 2016; 48(6):634–9. <https://doi.org/10.1038/ng.3561> PMID: 27135400
  43. Ruiz-Velasco N, Domínguez A, Vega MA. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. *Biochemical Pharmacology*. 2004; 67(2):303–13. PMID: 14698043
  44. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. *Journal of lipid research*. 1998; 39(4):777–88. Epub 1998/04/29. PMID: 9555943
  45. Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality—a systematic review. *BMC Public Health*. 2014; 14:14. <https://doi.org/10.1186/1471-2458-14-14> PMID: 24400816

46. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. *Asia Pacific journal of clinical nutrition*. 2012; 21(2):227–33. PMID: [22507609](https://pubmed.ncbi.nlm.nih.gov/22507609/)
47. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. *The Journal of clinical endocrinology and metabolism*. 2012; 97(7):2482–8. <https://doi.org/10.1210/jc.2011-3475> PMID: [22508708](https://pubmed.ncbi.nlm.nih.gov/22508708/)